Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass

Journal of Clinical Densitometry

Volumn 5, Issue 2, 2002, Pages 143-149

  Younes, Hashem ^a   Farhat, Ghada ^a   Fuleihan, Ghada El Hajj ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Bone density; Efficacy; Pamidronate; Responders; Tolerability

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PAMIDRONIC ACID; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERANCE; FEMALE; HIP; HUMAN; MALE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPINE; SUPPLEMENTATION; TIME; TREATMENT INDICATION; VITAMIN SUPPLEMENTATION; DRUG EFFECT; EVALUATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC BONE DISEASE; MIDDLE AGED; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; TREATMENT OUTCOME;

ADULT; AGED; BONE DENSITY; BONE DISEASES, METABOLIC; DIPHOSPHONATES; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0036021829     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1385/JCD:5:2:143     Document Type: Article

References (28)

1. Bisphosphonates: From the laboratory to the clinic and back again
2. Bisphosphonates: Mechanism of action
3. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
4. Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment
5. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
6. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double blind randomized, controlled trial
7. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
8. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized, controlled trial
9. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
10. Alendronate in early postmenopausal women: Effects on bone mass during long term treatment and after withdrawal
11. Effect of risedronate on the risk of hip fracture in elderly women
12. Esophagitis associated with the use of alendronate
13. Tolerability of oral bisphosphonates in patients with osteoporosis and other osteopathies
14. Pamidronate: An unrecognized problem in gastrointestinal tolerability
15. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
16. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastasis
17. Reduction in new metastasis in breast cancer with adjuvant clodronate treatment
18. Three monthly intravenous injections of ibandronate in the treatment postmenopausal osteoporosis
19. Cyclical pamidronate infusions in postmenopausal osteoporosis
20. Efficacy of intravenous pamidronate in osteoporosis, mineralometric evaluation
21. Treatment of postmenopausal osteoporosis with intravenous pamidronate in patients with esophagogastric pathology
22. Reproducibility of DXA absorptiometry: A model for bone loss estimates
23. Monitoring osteoporosis therapy with bone densitometry
24. The diagnosis of osteoporosis
25. Pamidronate: A review of its pharmacologic properties and therapeutic efficacy in resorptive bone diseas
26. Side-effects of pamidronate
27. The acute phase response after bisphosphonate administration
28. Paget's disease of bone: Early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD)